/PRNewswire/ 1:30 p.m. ET: UCB today announced that new data from its seizure treatment portfolio (BRIVIACT, NAYZILAM, and VIMPAT) will be showcased at the.
/PRNewswire/ 1:30 p.m. ET: UCB today announced that new data from its seizure treatment portfolio (BRIVIACT, NAYZILAM, and VIMPAT) will be showcased at the.
UCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
(2)
-
Nile is developing a digital epilepsy care management platform and bringing together data to make the epilepsy journey predictable
- UCB invested €25 million ($29.3 million) and as majority shareholder, will sit on the Board of Directors of Nile with future opportunities to acquire insights and data from Nile s platform
BRUSSELS and ATLANTA, Jan. 13, 2021 /PRNewswire/ UCB today announced the launch of Nile AI, Inc., a new independent company created to improve care for people living with epilepsy, their caregivers, and healthcare providers (HCPs). Nile was founded with a clear mission in mind: to make the journey of every epilepsy patient predictable. To that end, Nile is developing an epilepsy care management platform that serves as a digital extension of the healthcare provider (HCP) and provides patients with peace of mind between consultations, with the ultimate goal of shortening the path to optimal treatment.